This is educational information, not medical advice, and The Peptide University does not sell peptides, supplies, or supplements. Many compounds discussed here are sold as “research chemicals” and are not approved for human use outside of clinical trials. Laws vary by country, and nothing here is a recommendation to obtain or use anything. Talk to a qualified clinician about your own situation.
Retatrutide is an investigational drug from Eli Lilly, in Phase 3 trials at the time of writing and not approved by the FDA. It's discussed heavily online but is not a marketed medicine.
How it works
It's a single molecule that activates three receptors — GLP-1, GIP, and glucagon. The GLP-1/GIP arms curb appetite and blood sugar; adding glucagon-receptor activity is thought to also raise energy expenditure. See tirzepatide (dual) for the step below it.
The evidence
Phase 3 results reported by Lilly and covered in the press describe average weight loss in the high-20s percent (with even higher figures in extension cohorts) — the largest of the mainstream incretin class so far. Those results come from supervised trials with gradual escalation, not the top dose from day one.
Safety
The side-effect profile overlaps the rest of the class — predominantly gastrointestinal, dose-dependent — plus monitoring of heart rate and glucose given the glucagon activity. Read the GLP-1 side-effects article for the warning signs; they apply here.
FAQ
QHow is it different from tirzepatide?
Tirzepatide hits two receptors (GLP-1 + GIP); retatrutide adds glucagon for a third, giving a broader metabolic footprint.
QIs it available?
No — it's investigational and not FDA-approved as of writing. Status changes, so verify current information.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Retatrutide: what is it and is it FDA approved? (Drugs.com)
- Lilly Phase 3 retatrutide results (investor release)
- Next-gen weight-loss drug retatrutide trial (Scientific American)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Questions & comments
No account, no login — leave a name or stay anonymous. Ask a question, add something the article missed, or answer someone else. Be kind and cite sources where you can.